PSMA-RLT in Biochemically Recurrent PCa

This trial is testing PSMA-targeted radioligand therapy (PSMA-RLT) — a treatment that delivers targeted radiation directly to prostate cancer cells — in men whose prostate-specific antigen (PSA) level is rising after both surgery and radiation therapy for prostate cancer, even though no local recurrence is visible on scans. **You may be eligible if...** - You have prostate cancer with a rising PSA after both radical prostatectomy and radiation therapy - Your PSA doubling time is 12 months or less (rising quickly) - You have not been on hormone therapy in the past 12 months, or your testosterone has recovered - Your PSMA PET scan shows no local recurrence (distant spread is allowed) - You are in good overall health (ECOG 0–1) with adequate kidney and blood counts **You may NOT be eligible if...** - You are currently in another interventional clinical trial - You have severe urinary obstruction or unmanageable urinary leakage - You have a short life expectancy (less than one year) due to other serious conditions - You have significant psychiatric or physical conditions that would interfere with the study Talk to your doctor to see if this trial is right for you.